NCI-2022-10167

JZP815-101: Phase 1, FIH, open-label, nonrandomized, multicenter study of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway

This Phase 1 study is looking at a drug called JZP815-101, and it is an open-label, nonrandomized, multicenter study of JZP815 in participants with advanced or metastatic solid tumors that have mutations in the MAPK pathway. The study aims to assess the safety, tolerability, and preliminary effectiveness of JZP815.

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

MAPK pathway: The MAPK pathway is a communication system inside cells that regulates their growth, and when it malfunctions, it can contribute to cancer development

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05557045

Clinical Trial Site: Sinai

To see all available clinical trials click here.